Click it and Unblock the Notifications
Just In
Don't Miss
-
Wipro Q4 Results: Cons PAT Up 5% QoQ To Rs 2,834.6 Crore, Revenue Guidance Weaker Than Estimates -
Undekhi 3 OTT Release Date, Trailer, Cast: Atwala Back With Revenge Saga, When & Where To Watch -
KKR vs RCB: What Happened when KKR and RCB met Last Year in IPL 2023? -
Porsche Introduces Macan EV In India, Expanding Electric Portfolio -
NLSIU Announces the Rajiv K. Luthra Foundation Grant -
Dell Introduces AI-Powered Laptops and Mobile Workstations for Enterprises in India -
Summer Fashion: Your Bollywood Style White Outfits Guide To Keep It Cool And Chic -
Journey From Delhi To Ooty: Top Transport Options And Attractions
COVID-19: Dexamethasone trial results confirm both benefits and risks
Washington, July 18: The full results from a UK trial of the steroid dexamethasone were published on Friday. It has confirmed its life saving benefits for COVID-19 patients on ventilators, but suggested it may cause harm if given too early.
Recommended Video
In all 2,104 hospitalised patients were assigned to receive 6 milligram daily doses of the medicine for up to 10 days. 4,321 were to receive usual care, with the rate of deaths compared after 28 days.
Among those patients on ventilators, the rate of death for patients on the drug was 29.3 per cent when compared to 41.4 per cent on those without. This means that there was a reduction of 29 per cent in mortality.
However, there were no benefits among the group who were not receiving any oxygenation at the time the trial started. 17.4 per cent on the steroid died compared to 14 per cent who did to receive it, suggesting that the drug increased their mortality rate.
